Febuxostat-Charcoal Combo Fails to Improve Urate Control but Reduces Gout Flares in RCTGout study finds combination treatment reduces flares but not urate levels

The American journal of medicine Published April 4, 2026 Study authors: Guo Kai, Sun Mingshu, Hu Shuhui, Wang Xuefeng, Ji Xiaopeng, Chen Ying, Cui Lingling, Liu Zhen, Li Xi… PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note flare reduction with febuxostat-charcoal combo, but it did not improve primary urate-lowering efficacy.

A 24-week randomized controlled trial evaluated 348 patients with primary gout. It compared febuxostat 20 mg combined with activated charcoal (4.5 g or 7.2 g) against febuxostat 20 mg or 40 mg monotherapy. The primary outcome was the proportion achieving a serum urate level below 360 μmol/L. The combination regimen did not demonstrate superior efficacy for this urate-lowering endpoint compared to monotherapy.

For secondary outcomes, the combination regimen significantly reduced the rates of patients experiencing ≥1 flare and ≥3 flares compared to both monotherapy groups (P < 0.05 and P < 0.01, respectively). It also significantly prolonged the time to the first flare and resulted in significantly lower low-density lipoprotein cholesterol levels at week 24. Specific effect sizes and absolute event numbers for these outcomes were not reported.

The incidence of adverse events was similar across all treatment groups. The study did not report on serious adverse events, discontinuation rates, or tolerability specifics. Key limitations include the lack of reported absolute numbers and effect sizes for the positive secondary outcomes, and the primary urate-lowering objective was not met. The clinical relevance of the flare reduction and LDL-C benefit, while notable, is tempered by the failed primary endpoint and requires confirmation in studies designed with these as primary goals.

Researchers tested whether adding activated charcoal to the standard gout medication febuxostat would help people with gout. They studied 348 patients with primary gout over 24 weeks, comparing different doses of the combination treatment against febuxostat alone.

The combination treatment did not work better than febuxostat alone at lowering urate levels in the blood, which is the main goal of gout treatment. However, patients taking the combination had fewer painful gout flares, experienced their first flare later, and had lower cholesterol levels at the end of the study.

Safety appeared similar across all treatment groups, though the study didn't report details about serious side effects or why people might stop treatment. The main reason to be careful is that reducing flares and cholesterol were secondary goals of the study, while the primary goal of lowering urate wasn't improved.

Readers should understand this is one study showing a possible benefit for reducing flares, but it didn't improve the main treatment target. People with gout should talk with their doctor about their treatment options rather than making changes based on this single study.

What this means for you:

One study found adding charcoal to gout medication reduced flares but didn't improve main treatment goal.

Study Details

Study typeRct

Sample sizen = 348

EvidenceLevel 2

Follow-up0.9 mo

PublishedApr 2026

PMID41547464

View Original Abstract ↓

BACKGROUND: Activated charcoal (AC), a known adsorbent in the gastrointestinal tract, has been reported to reduce serum urate (SU) levels. This study aimed to assess the efficacy and safety of AC in managing primary gout. METHODS: This double-blind, double-dummy, randomized controlled trial involved 348 patients, who were randomly assigned to one of four groups: febuxostat 40 mg, febuxostat 20 mg + AC 4.5 g, febuxostat 20 mg + AC 7.2 g, and febuxostat 20 mg. Patients were followed-up every 4 weeks until week 24. The primary endpoint was the proportion of patients achieving SU level < 360 μmol/L. RESULTS: All 348 enrolled patients were included in analysis. The febuxostat-AC combination regimen didn't demonstrate superior efficacy in controlling SU levels. However, the combination regimen significantly reduced flare rates compared to the febuxostat 20 mg group (≥ 1 and ≥ 3 flares, P < 0.05) and the febuxostat 40 mg group (≥ 1 flare, P < 0.05; ≥ 3 flares, P < 0.01), and it also significantly prolonged the time to first flare. Additionally, the combination regimen resulted in significantly lower low-density lipoprotein cholesterol (LDL-C) levels at week 24. The incidence of adverse events was similar across the groups. CONCLUSIONS: The febuxostat-AC combination regimen didn't enhance urate-lowering effects but significantly reduced gout flare frequency, delayed the onset of first flare, and improved LDL-C levels. These findings underscore the role of AC in comprehensive gout management. TRIAL REGISTRATION: ChiCTR, http://www.chictr.org.cn, ChiCTR2000034138.

Febuxostat-Charcoal Combo Fails to Improve Urate Control but Reduces Gout Flares in RCTGout study finds combination treatment reduces flares but not urate levels

Study Details

Late-onset rheumatoid arthritis shows higher DAS28 scores and lower remission rates compared to young-onset disease in a meta-analysis

Meta-analysis compares treatment outcomes in older versus younger rheumatoid arthritis patients

Clinical research that matters. Delivered to your inbox.

Febuxostat-Charcoal Combo Fails to Improve Urate Control but Reduces Gout Flares in RCTGout study finds combination treatment reduces flares but not urate levels

More on Gout

Study Details

Late-onset rheumatoid arthritis shows higher DAS28 scores and lower remission rates compared to young-onset disease in a meta-analysis

Meta-analysis compares treatment outcomes in older versus younger rheumatoid arthritis patients

Clinical research that matters. Delivered to your inbox.

Related in Rheumatology

From Other Specialties